Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Assets: 2017-2024

Historic Current Assets for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $126.0 million.

  • Aclaris Therapeutics' Current Assets fell 23.98% to $100.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.6 million, marking a year-over-year decrease of 23.98%. This contributed to the annual value of $126.0 million for FY2024, which is 2.25% down from last year.
  • Aclaris Therapeutics' Current Assets amounted to $126.0 million in FY2024, which was down 2.25% from $128.9 million recorded in FY2023.
  • Aclaris Therapeutics' Current Assets' 5-year high stood at $231.6 million during FY2022, with a 5-year trough of $57.5 million in FY2020.
  • In the last 3 years, Aclaris Therapeutics' Current Assets had a median value of $128.9 million in 2023 and averaged $162.1 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Current Assets skyrocketed by 256.62% in 2021, and later crashed by 44.35% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Current Assets (Yearly) stood at $57.5 million in 2020, then surged by 256.62% to $205.0 million in 2021, then climbed by 12.93% to $231.6 million in 2022, then crashed by 44.35% to $128.9 million in 2023, then dropped by 2.25% to $126.0 million in 2024.